Iambic Therapeutics, Inc. · Conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for Iambic Therapeutics, Inc. records a conversion involving Common Stock on October 16, 2026. The reported quantity was 1,458,736. The filing date is October 19, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2

Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3

The shares are held of record by Ascenta Capital Fund I, L.P., or Ascenta Capital Fund I. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Fund I, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Fund I. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

F4

The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).

F5

The shares are held of record by Ascenta Capital Project Turing SPV, L.P., or Ascenta Capital Project Turing. As a Managing Member of Ascenta Capital Fund I, G.P., L.L.C., the General Partner of Ascenta Capital Project Turing, the reporting person shares voting and dispositive power with respect to the shares held of record by Ascenta Capital Project Turing. The reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.